

Date: September 14, 2016

To  Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUROPHARMA</b>	To  The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
--	--

Dear Sirs,

**Sub: Presentation to the Investors / Analysts.**

The Company is participating in the India Investor Summit being organized by JP Morgan tomorrow, 15<sup>th</sup> September, 2016 in Delhi at 9.00 a.m. In this connection, we enclose herewith the presentation that would be made to the investors in the said summit. It may please be noted that this presentation is the same one that was presented to the investors/analysts on 29<sup>th</sup> August 2016 and the same was intimated to you vide our letter dated 29<sup>th</sup> August, 2016 and was also made available on our website in the following link:

<http://www.aurobindo.com/docs/annual-reports/aurobindo-pharma-ltd-investor-presentation-august-2016.pdf>.

Please take the information on record.

Thanking you,

Yours faithfully,  
**For AUROBINDO PHARMA LIMITED**

  
**B.ADI REDDY**  
Company Secretary



**AUROBINDO PHARMA LIMITED**

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

[www.aurobindo.com](http://www.aurobindo.com)



AUROBINDO

INVESTOR PRESENTATION

August 2016



# Disclaimer

---



This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance.

While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that we have indicated could adversely affect our business and financial performance.

Aurobindo Pharma undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances.


For updates and specific queries, please visit our website [www.aurobindo.com](http://www.aurobindo.com)

# Company Overview



- Among the Top-5 listed pharmaceutical companies from India by sales<sup>(1)</sup> and market capitalization<sup>(2)</sup>
- Well entrenched US portfolio of 403 filed ANDAs including 228 final approved
- Vertical integration with in-house API for around 75% of its Formulation products
- Continued focus on the base business while capitalizing on the complex molecules, differentiated technology platforms and specialty products
- Global presence with 90% of sales from international markets, spanning across more than 150 countries
- 23 API and Formulation Manufacturing Units with 3 in US and 1 in Brazil
- Global footprints with over 15,000 employees

## Net Operating Income (INR Cr)



1) FY16 Sales; 2) As on 31 March 2016; \*As per Ind AS

## Top 10 Therapy Segments

Category	Size (US\$ Bn)	APL's presence
Oncology	74.5	✓
Anti-diabetics	63.6	✓
Pain / acute	59.8	✓
CNS	47.5	✓
Anti-bacterials	40.3	✓
Respiratory	39.6	✓
Mental health	39.1	✓
Anti-viral	35.9	✓
Lipid Regulator	28.4	✓
Dermatology	28.2	X

## Top 10 Generics Markets

Markets	% share	APL's presence - FDF	APL's presence - API
USA	40%	✓	✓
Japan	10%	X	✓
France	6%	✓	✓
Germany	6%	✓	✓
Italy	4%	✓	✓
Spain	3%	✓	✓
UK	3%	✓	✓
China	3%	X	✓
Brazil	2%	✓	✓
Mexico	2%	✓	✓

# The Journey So Far...



## Creation of a leading vertically integrated platform

- Commencement of export of APIs
- Initial Public Offering (1995)
- Began production of formulations

- Acquired formulations facility in USA and Pharmacin (now Aurex) in Netherlands
- Investment in building manufacturing, marketing & IPR capabilities

- First approval of Controlled Substance formulations in USA
- Set up Auro Peptide to foray into Peptide business

- Acquired Western European commercial operations from Actavis and US Nutraceuticals company, Natrol
- Focus on differentiated technology platforms eg. depot injections

1992 – 2003

2006

2007

2010

2012

2013

2014

2015

- Acquired UK based Milpharm

- Commenced operations of SEZ Unit VII and Aurolife, USA facilities and divested Chinese antibiotics facility

- Commenced marketing specialty injectables products in USA through AuroMedics
- Building capabilities in Penem, Oncology & Biocatalysis

- Investment into Tergene to fund the development of a pneumonia vaccine

API Focus

Foray into  
Finished  
Dosage  
Formulations

Establishing Global  
Footprint



Consolidating Presence in  
US and EU + Expanding  
Injectables & Differentiated  
Offerings

# Strong Operational Growth



INR Cr	FY13	CAGR	FY16
Net Revenue	5,855	33%	13,896
EBITDA	889	53%	3,206
EBITDA Margin (%)	15.2%		23.1%
PAT	294	89%	1,982
PAT Margin (%)	5.0%		14.3%
ANDA Filed	269		398

## Revenue Breakup



\*EM: Emerging Markets

# Our Business Segments




## US

- Ranked 7<sup>th</sup>\* Rx supplier as per IMS total prescription dispensed
- Differentiated pipeline with new launches including injectables, ophthalmics, speciality products and controlled substances
- Expanded presence in nutraceutical business through Natrol
- Manufacturing and R&D presence including Controlled substances

## API

- Cost effective with vertical integration of around 75% of API requirement sourced internally
- One of the leading supplier of APIs from India - serves as a source for various Gx and branded drugs
- Strong regulatory capability with 206\*\*\* US DMF filings



## EU

- Among top 15\*\* Gx companies by sales
- Focus markets are France, Germany, Netherlands, Spain, UK, Portugal and Italy
- Augment position through new product launches and extension to selected Eastern Europe markets

## ARV - Institutional

- Focus on global tenders; availability across >100 countries
- Maintain competitiveness through development of new products

## Emerging Markets

- Focus on major markets viz Brazil, South Africa, Ukraine, and Mexico
- Expansion into selective markets of Asia Pac, Africa & Middle East

\*Source: IMS National Prescription Audit, Total Prescriptions Dispensed, Twelve months ending April 2016

\*\*Source: Market Reports, \*\*\*as on 30 June 2016

# US Business Overview



**Aurobindo USA**  
Oral Rx


**AuroMedics**  
Injectables

**AuroLife Pharma**  
Manufacturing /  
R&D


**AuroHealth**  
Pharma OTC

**Natrol**  
Nutraceuticals

## Cumulative ANDA Filings and Approvals



## Gross Sales (INR Cr)



Tentative Approvals include 21 ANDAs approved under PEPFAR

## Unit wise ANDA Filings as on 30-June-2016

Site	Details	Final Approval	Tentative Approval	Under Review	Total
Unit III	Oral Formulations	93	19	12	124
Unit IV	Injectables & Ophthalmics	31	2	35	68
Unit VB	Cephalosporins Oral	11			11
Unit VII (SEZ)	Oral Formulations	61	20	70	151
Unit XII	Penicillin Oral & Injectables	19			19
AuroLife USA	Oral Formulations	13		13	26
AuroNext	Penem Injectables			4	4
<b>Total</b>		<b>228</b>	<b>41</b>	<b>134</b>	<b>403</b>

- Broad product portfolio mix complemented with the introduction of high value products
- Strong Pipeline of sterile products incl. ophthalmic, respiratory, oncology, hormones and penems


\*As per Ind AS



# US: Expanding Portfolio Mix Towards High-value Products



Portfolio mix is complemented with the introduction of high-value products



Addressable Market at US\$ 76.4 Bn including ~US\$ 50.1 Bn for Under Review and Tentatively approved ANDAs

Future pipeline to include Oncology, Hormones, Depot injections, Inhalers, Patches & Films

Addressable market refers to the market size as per IMS. Data is for the total 403 ANDAs filed by the company

\*Does not include the addressable market of the products approved under PEPFAR

Source: IMS Data, June 2016



- Amongst the top 20 branded nutraceuticals companies in US
- Diverse Customer Base with long term relationships with key distribution and retail partners
- Strong customer partnerships across multiple distribution channels with growth potential within each channel
- R&D capabilities in new innovative delivery formats as time release, fast dissolve and natural foam
- Inhouse manufacturing capability & regulatory expertise for quality product at competitive prices
- Synergies
  - Expand presence in other attractive global markets
  - Enhance the Research and Development expertise through collaborations



Key Product Segment	
Vitamins, Minerals & Supplements	Sports Nutrition
Diet & Weight Mgt	Hair, Skin & Nails
Favourable Demand Drivers	
Ageing population	Fitness Focus
Consumer awareness	Rising HC costs

# EU Business Overview



France

Germany

Netherlands

Spain

UK

Portugal

Italy

Romania


Belgium

- India's Leading Gx company with strong footprint in Europe
  - Operations in 9 countries with full fledged sales force & support infrastructure
  - Significant presence and position in Top 5 EU markets led by France & Germany
  - Commercialized over 450 INNs across 9 countries of operation
- Presence across Gx, TGx, BGx and Hx segment with established commercial and hospital sales infrastructure
- Expanded analytical testing facilities for sterile and non-sterile products in Malta
- Pipeline of over 200 products under development

## Business Strategy

- Consolidate presence & improve position among Top 10 players in each market
- Expanding into new geographies viz Poland and Czech Republic
- Portfolio Expansion through targeted Day 1 launches; Orals, Hormonals & Penems, Oncology Products, Niche Injectables, Low volume Injectables
- Lower generics penetration in Italy, Spain & France offer future growth potential as share of generics improves


Gross Sales (INR Cr)




# EU: Portfolio Mix Across Channels




Sales split by Channel



Sales split by Therapeutic Profile



Sales split by Dosage Forms



Channels	Gx	BGx	Hx	TGx
Geographies	All 9 countries	7 countries	All 9 countries	Germany, Spain & Netherlands
# of Products	761 (primarily tablets & capsules)	34	343 (predominantly injectables)	765 (including Gx products)
Other Highlights	Amongst top 10 in most markets	Includes leading brands such as Neotigason, Floxapen, Bezalip among others	Focus on high value areas including oncology	Tender based business

# ARV Business Overview




- Focus on global tenders floated by Multi-Lateral Organizations like Global Fund, USAID/PEPFAR and Country specific MOH tenders; currently caters to 2.2 million HIV+ patients
- Well integrated supply chain management services and logistics for ARV supplies (29 products) catering to over 100 countries
- Filed over 1,100 ARV dossiers for registrations across the globe.

## Dolutegravir (DTG) – The Next Growth Driver

- Aurobindo is the first generic company to sign license with ViiV Healthcare for the next generation Integrase Inhibitor – DTG
  - Filed an ANDA application for DTG 50mg with USFDA under the PEPFAR program.
  - WHO announced this drug as a 1<sup>st</sup> line reserve drug in its 2015 HIV treatment guidelines
  - Play a collaborative role in upgrading millions of patients to the latest best in class ARV drug
- Developing a Triple drug combination containing DTG
- Market size is expected to be \$ 2bn\* in 2017; Triple combination drug containing DTG expected to garner major share

Gross Sales (INR Cr)



Products
Efavirenz+Lamivudine+Tenofovir
Zidovudine + Lamivudine + Nevirapine Tabs
Lopinavir + Ritonavir Tabs
Lamivudine + Zidovudine Tabs
Abacavir Sulfate Tabs
Efavirenz+Emtricitabine+Tenofovir Tabs
Lamivudine Tabs

\*Source: Market Report of Clinton Health Access Initiative(CHAI) and WHO global forecast report; \*\*As per Ind AS

# Emerging Markets Business Overview




- Focus markets include Brazil, South Africa, Ukraine and Mexico
- Geographic diversification through expansion into selective markets of Asia Pacific, Africa, Middle East etc

## Opportunity to Leverage

- Build branded generics presence
- Enhance penetration in selected emerging markets through local manufacturing units
- Expand presence with Therapeutic Areas like Oncology and specialty injectables

Gross Sales (INR Cr)




# The Base Business : API




- Focus on high value, specialty, small/mid-size products with a limited competition
- Amongst the most vertically integrated generic pharma platforms with API integration for around 75% of its products; offers cost competitiveness and high process chemistry skills coupled with commitment to quality
- Quality & Reliability of supplies and ability to command cost efficiencies as well as economies of scale
- Growing into more advanced regulated market (EU, Japan & USA)
- Facilities meet regulatory standard of advanced market regulators as USFDA, UK MHRA, EU, Japan PMDA, Mexico COFEPRIS, Brazil-ANVISA, Korea FDA etc
- Manufacturing capacities has been enhanced by adding large volume blocks at Vizag to support growth

Gross Sales (INR Cr)



Strong Regulatory Capability\*



\*As on 30 June 2016 (excludes Multiple registrations); \*\*As per Ind AS

# Consolidated Financials



Value INR Cr	Q1 FY17	Q1 FY16	% Change
Formulations	3,032.1	2,615.7	15.9%
API	734.5	722.9	1.6%
<i>Formulations % of sales</i>	<i>80.5%</i>	<i>78.3%</i>	
<b>Net Operating Income</b>	<b>3,725.9</b>	<b>3,298.9</b>	<b>12.9%</b>
<b>Gross Margin</b>	2,088.9	1,786.6	16.9%
	<b>56.1%</b>	<b>54.2%</b>	
Overheads	1,200.0	1,061.5	13.0%
<b>EBIDTA</b> (excl. Fx & other income)	889.0	725.0	23.9%
	<b>23.9%</b>	<b>22.0%</b>	<b>188 bps</b>
Fx (Gain) / Loss	(7.0)	10.6	
Other Income	15.9	29.4	
Finance Cost	20.6	20.8	
Depreciation	106.2	89.0	
<b>PBT from ordinary activities</b>	<b>785.0</b>	<b>634.0</b>	<b>23.8%</b>
<b>PAT (after JV share, minority interest and OCI)</b>	<b>584.6</b>	<b>471.3</b>	<b>24.0%</b>
<b>EPS</b>	<b>10.0</b>	<b>8.1</b>	<b>23.8%</b>
<b>Avg Fx Rate US\$ 1= INR</b>	<b>66.8255</b>	<b>63.29</b>	

PAT Reconciliation (INR Cr)	Q1 FY16
As per IGAAP	432.4
Impact on deferred tax (including on unrealized intragroup profits on inventories)	22.9
Impact on foreign currency exchange differences	15.7
Difference in measurement of employee benefit expenses	1.9
Other Ind AS adjustments	(0.5)
<b>As per Ind AS</b>	<b>472.5</b>
Other Comprehensive Income	(1.15)
<b>Profit after OCI</b>	<b>471.3</b>


As per Ind AS




# Financial Performance




## Sales (INR Cr)




## EBITDA & PAT Margin (%)




## EPS (INR/Share)




## Gross Block & Fixed Asset Turnover



## Average ROE & ROCE %




## Net Debt/Equity & Net Debt/EBITDA



# Debt Profile



## Fx Loan US\$ Mn



Debt as on (INR Cr)	Mar-15	Mar-16	June-16*
Closing Rate <sup>1</sup> US\$ = INR	62.50	66.255	67.525
Fx Loan restated in INR	4,312.3	4,956.7	4,661.4
Rupee Loan	37.3	46.9	46.5
Sales Tax Deferment	54.9	41.9	0.5
<b>Gross Debt</b>	<b>4,404.5</b>	<b>5,045.6</b>	<b>4,708.5</b>
Cash Balance	450.8	805.2	1,161.9
<b>Net Debt</b>	<b>3,953.6</b>	<b>4,240.3</b>	<b>3,546.5</b>
<b>Net Debt (US\$ Mn)</b>	<b>632.6</b>	<b>640.0</b>	<b>525.2</b>
<b>Finance Cost</b>	<b>1.9%</b>	<b>1.8%</b>	<b>1.8%</b>

- Other Term Loans (Subsidiaries) & Unsecured Loans
- ECB - APL
- Working Capital

Numbers as per Ind AS

Debt includes bill discounting

\*Gross Debt is after netting off debt factoring of US\$ 150 Mn

Fx Debt and Fx Cash Balance are reinstated

# New Business and Technology Initiatives to Support Growth



## Peptides

- Manufacturing peptides from short to long chain molecules supporting mg to kg scale
- Highly Experienced team of scientists; developed technologies for over 10 products
- Three DMFs filed; work ongoing on more products
- Forward integrating by developing microspheres with an addressable market of US\$ 3bn

## Oncology and Hormones

- Dedicated R&D center and manufacturing facility set up to develop and manufacture oncology and hormonal products, both for solid and parenteral dosage forms
- Current Product Portfolio includes 6 hormonal products & 57 Oncology products
- Exhibit batches for over 15 Oncology products & 5 hormonal products are scheduled in FY16-17

## Enzymes

- Develops biocatalysts with applications in the pharma and chemical industry
- Provides chemical transformations screening and invention of new routes utilizing biocatalysis
- Supplies AuroZymes Enzyme screening panels and supports any scale of manufacturing

## Vaccines

- JV to develop pneumococcal conjugate vaccine
- Efforts to achieve commercial launch of branded products in 2018

## Other Technology Initiatives

Working on differentiated technology platforms viz Depot injections, Inhalers, Patches and Films

# Key Investments for Future Growth

---



## Brownfield Expansions

- ▶ New dedicated block for lyophilized vials at Unit IV (General Injectable facility), India
- ▶ New finished dosage formulations blocks at Unit VII (SEZ), India
- ▶ Substantial capacity expansion at AuroLife, USA

## Greenfield Projects

- ▶ Oral Solid finished dosage formulations facility at Naidupet (SEZ), India
- ▶ Commissioned specialty products (Hormones and Oncology) facility (Eugia), India
- ▶ Finished dosage formulations for European markets at Vizag, India
- ▶ New campus at USA for central automated warehouse, OTC liquids & packaging facility and Others
- ▶ New Formulations Development center in USA

# Way Forward



\*As on 30 June 2016

Oral segment includes 'Under PEPFAR' tentatively approved ANDAs



---

# Annexure

# Sales Break-Up



INR Bn	FY14				FY15				FY16				FY17
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1*
USA	6.2	7.3	9.3	11.2	11.2	11.7	12.0	13.4	14.3	14.8	15.7	16.7	17.0
Europe	1.7	1.7	1.5	1.8	8.0	7.7	8.6	7.7	7.4	7.6	7.8	8.4	8.3
Emerging Market	1.1	0.9	1.3	1.3	1.4	1.6	1.3	1.4	1.7	1.7	1.8	1.8	1.9
ARV	1.9	2.3	2.2	1.9	2.2	1.4	3.3	2.7	3.0	2.7	3.1	3.3	3.0
<b>Formulations Sales</b>	<b>11.0</b>	<b>12.3</b>	<b>14.4</b>	<b>16.1</b>	<b>22.8</b>	<b>22.4</b>	<b>25.3</b>	<b>25.2</b>	<b>26.4</b>	<b>26.8</b>	<b>28.4</b>	<b>30.1</b>	<b>30.3</b>
Betalactum	4.4	4.5	4.8	4.8	4.5	4.5	4.6	4.4	4.8	4.3	4.5	5.0	4.9
Non-Betalactum	2.1	2.7	2.7	2.7	2.2	2.4	2.2	2.4	2.5	2.6	2.5	2.7	2.4
<b>API Sales</b>	<b>6.5</b>	<b>7.2</b>	<b>7.4</b>	<b>7.5</b>	<b>6.7</b>	<b>6.9</b>	<b>6.7</b>	<b>6.8</b>	<b>7.2</b>	<b>6.9</b>	<b>7.0</b>	<b>7.7</b>	<b>7.3</b>
Gross Sales	17.5	19.5	21.8	23.7	29.5	29.2	32.0	31.9	33.6	33.7	35.3	37.9	37.7
<b>Formulations as % of Gross Sales</b>	<b>63%</b>	<b>63%</b>	<b>66%</b>	<b>68%</b>	<b>77%</b>	<b>77%</b>	<b>79%</b>	<b>79%</b>	<b>78%</b>	<b>80%</b>	<b>80%</b>	<b>80%</b>	<b>80%</b>

- Formulations segment witnessed continuous growth and is now 80% of total sales up from 63% in Q1 FY14
- Vertical integration with in-house API for around 75% of its Formulation products

# 5 Year Financial Snapshot



Value INR Bn	FY12	FY13	FY14	FY15	FY16
<b>Net Operating Income</b>	<b>46.3</b>	<b>58.6</b>	<b>81.0</b>	<b>121.2</b>	<b>138.9</b>
Gross margin % of operating income	45.5%	48.9%	55.5%	54.6%	55.7%
EBITDA (before Fx and other income) % to Operating income	13.2%	15.2%	26.4%	21.2%	23.1%
Depreciation / Amortization	2.0	2.5	3.1	3.3	3.9
Finance Cost	1.0	1.3	1.1	0.8	0.9
<b>PBT (before exceptional item)</b>	<b>1.1</b>	<b>3.7</b>	<b>15.3</b>	<b>21.7</b>	<b>27.2</b>
<b>PAT before exceptional items</b>	<b>2.0</b>	<b>2.9</b>	<b>11.7</b>	<b>15.7</b>	<b>19.8</b>
Total Shareholder Funds	23.4	26.1	37.5	51.6	70.6
Total Gross Debt	31.0	34.4	37.7	44.6	47.1
Net Debt	30.3	32.3	35.9	39.9	38.7
Gross Fixed Assets (net of Goodwill)	30.3	37.1	41.1	49.1	57.6
<b>Ratios</b>					
Gross Debt / Shareholders' funds (x)	1.3	1.3	1.0	0.9	0.7
Net Debt / EBIDTA (x)	5.0	3.6	1.7	1.6	1.2
Asset Turnover Ratio (x)	1.7	1.7	2.1	2.7	2.6



# Filing details as on 30<sup>th</sup> June 2016



Category	As at Mar 13	As at Mar 14	As at Mar 15	As at Mar 16	As at June 16	Approvals
Formulations						
US*	269	336	376	398	403	269 (FA: 228, TA:41)
Europe**	1,341	1,542	1,756	2,224	2,327	1,380 Dossiers (154 products)
SA**	314	334	345	376	379	168 Registrations (84 products)
Canada***	49	72	83	105	110	87 products
<b>Total</b>	<b>1,973</b>	<b>2,284</b>	<b>2,560</b>	<b>3,103</b>	<b>3,219</b>	
API						
US	172	181	192	205	206	
Europe**	1,443	1,504	1,601	1,689	1,701	
CoS	109	106	114	118	121	
Others**	565	627	681	715	722	
<b>Total</b>	<b>2,289</b>	<b>2,418</b>	<b>2,588</b>	<b>2,727</b>	<b>2,750</b>	

In total 385 APIs are filed across geographies with multiple registrations

\*Includes filings made from AuroLife Pharma LLC, USA (net of ANDAs withdrawn)

\*\*includes multiple registration; \*\*\*excludes withdrawn

For Europe Formulations, as on 30 June 2016 additional 1,641 MAs have been transferred from Actavis

# Extensive Manufacturing Base with High Quality Control and Compliance



## Finished Dose Formulations

Site	Product Capabilities
Unit III	Non antibiotics, ARVs / Orals
Unit IV	Injectables (Non-antibiotics)&Ophthalmics
Unit VI B	Cephalosporin / Orals
Unit VII	Non antibiotics, ARVs / Orals
Unit XII	Antibiotics, injectables, Orals
AuroNext	Penem formulations
Brazil Unit	Antibiotics
Eugia*	Oncology & Hormones
AuroLife	Non antibiotic & Controlled substances
AuroHealth	Pharma OTC / Orals and Liquids
Natrol	Nutraceuticals
Unit X*	Non antibiotics, Solid Orals
Unit XV	Non antibiotics, Solid & Liquid Orals (EU)
Unit XVI*	Antibiotics, Injectables
APL Healthcare	Pharma OTC, Solid Orals

Large manufacturing capabilities approved by key regulators for a diversified product portfolio with technology & expertise for specialty formulations

Vertically integrated operations from conception to commercialization

\* Under construction / Yet to be operationalized

## Active Pharma Ingredients

Site	Product Capabilities
Unit I	CVS, CNS, Anti-Allergics, Non-Sterile
Unit IA	Cephalosporin
Unit II	Intermediates for non antibiotics, Penems
Unit V	Antibiotics (Sterile & Non-sterile)
Unit VIA	Cephalosporins (Sterile)
Unit VIII	ARV, CVS, CNS (Non-sterile)
Unit IX	Intermediates
Unit XI	Non antibiotics
Unit XI U	Antibiotics (Non-sterile)
Unit XIV	CVS, Anti fungal
Silicon LS	Penems (Non-sterile)
AuroNext	Penems (Sterile)
AuroPeptide	Peptides

High specification manufacturing plants approved by key regulators equipped by site dedicated control laboratories located in India


API plants equipped with particle size modifications systems to supply compacted and micronized materials

# Shareholding Pattern



Group	As on 31 Mar 15	As on 31 Mar 16	As on 30 June 16
Promoter Group	54.0%	53.9%	53.9%
FII	29.6%	27.4%	26.1%
MF / Insurance	6.2%	7.2%	7.7%
Other Bodies Corporates	1.6%	2.4%	3.1%
Retail Investors	8.6%	9.1%	9.2%
<b>Total</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>
Equity Shares (in Cr)	29.2	58.5	58.5
Face Value (INR)	1	1	1
Equity Capital (INR Cr)	29.2	58.5	58.5
M-Cap at close (INR Bn)	356.7	435.9	434.5
Shareholder family (# '000)	75.2	115.9	128.2

## Non-Promoter Holding 46.1%





# Thank You



For updates and specific queries, please visit our website [www.aurobindo.com](http://www.aurobindo.com)

Investor Relations:

Deepika Gupta Padhi

Phone: +91-40-66725000/5401

+91 98486 67906

Email: [ir@aurobindo.com](mailto:ir@aurobindo.com)

Corporate Office:

Water Mark Building, Level-1, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084

Registered Office:

Plot No. 2, Maitrivihar, Ameerpet, Hyderabad – 500038